|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Dermatitis, Atopic | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Dermatitis | |||||
| 3 | More general conditions related to this trial | ||||
| Genetic Diseases, Inborn | |||||
| Hypersensitivity | |||||
| Hypersensitivity, Immediate | |||||
| Immune System Diseases | |||||
| Skin Diseases | |||||
| Skin Diseases, Eczematous | |||||
| Skin Diseases, Genetic | |||||
| 4 | Interventions listed in this trial | ||||
| tacrolimus 0.1% | |||||
| fluticasone 0.005 % | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Fluticasone | |||||
| Tacrolimus | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Allergic Agents | |||||
| Anti-Asthmatic Agents | |||||
| Anti-Inflammatory Agents | |||||
| Autonomic Agents | |||||
| Bronchodilator Agents | |||||
| Dermatologic Agents | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Respiratory System Agents | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Astellas Pharma Inc | |||||